Neurocrine Biosciences (NBIX) Assets Average (2011 - 2026)

Neurocrine Biosciences' Assets Average history runs 16 years deep, the most recent figure standing at $4.8 billion for Q1 2026.

• Quarterly Assets Average rose 28.78% year-over-year to $4.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 28.78% YoY) and the FY2025 annual result came in at $4.2 billion, up 19.8% from the prior year.
• Assets Average was $4.8 billion for Q1 2026 at Neurocrine Biosciences, up from $4.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $4.8 billion in Q1 2026 and bottomed at $2.1 billion in Q3 2022.
• A 5-year average of $3.2 billion and a median of $3.4 billion in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average climbed 4.41% — and 2024, when it soared 42.2%.
• Neurocrine Biosciences' Assets Average stood at $2.3 billion in 2022, then surged by 35.18% to $3.0 billion in 2023, then rose by 18.92% to $3.6 billion in 2024, then gained by 22.66% to $4.4 billion in 2025, then increased by 7.2% to $4.8 billion in 2026.
• Business Quant data shows NBIX's Assets Average at $4.8 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.1 billion in Q3 2025.